A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC)
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer
Interventions: DRUG: SG001|DRUG: Nab-paclitaxel
Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.